Medtronic ALgorithm using LINQ Sensors for EValuation And TreatmEnt of Heart Failure (ALLEVIATE-HF)
ALLEVIATE-HF: Algorithm Using LINQ Sensors for Evaluation And Treatment of Heart Failure
Sponsor: Medtronic
Enrolling: Male and Female Patients
IRB Number: AAAT3033
U.S. Govt. ID: NCT04452149
Contact: Kate Dalton: 347-514-3366 /
Additional Study Information: The ALLEVIATE-HF study is a prospective, randomized, multi-site, interventional, investigational device exemption (IDE) study. The purpose of the study is to gain experience with utilization of an integrated device diagnostic-based risk stratification algorithm to guide patient care in subjects with NYHA class II and III heart failure. The study will utilize the market-released Reveal LINQ Insertable Cardiac Monitor with an investigational ALLEVIATE-HF RAMware download. The study will enroll up to 300 subjects at up to 30 sites in the US and will characterize the safety of the patient management pathway. Subjects will be followed for a minimum of 7 months, and until study closure.
Kelly Axsom, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with Heart Failure? Yes No
Have you been hospitalized within the last 12 months for Heart Failure or have received inotropic therapy? Yes No
Have you been implanted with a cardiovascular electronic device? (CRT, ICD, or CardioMEMS) Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Kate Dalton